2019.09.06 12:41Business

大日本住友、海外製薬ロイバントと戦略提携＝３２００億円でグループ各社の株取得

　大日本住友製薬は６日、英ロンドンとスイス・バーゼルに本社を置く製薬企業ロイバント・サイエンシズと戦略提携することで基本合意したと発表した。ロイバントの一部株式に加え、同社の５子会社の株式も取得し、収益基盤の強化を図る。（2019/09/06-12:41）

英文版に切り替え

2019.09.06 12:41Business

Sumitomo Dainippon Pharma to Invest 3 B. Dollars in European Startup

Twitter

Facebook

LINE

Sumitomo Dainippon Pharma Co. said Friday it has struck a 3-billion-dollar investment deal with Roivant Sciences Ltd., a European drug startup.
The basic agreement, aimed at capitalizing on Roivant's drug development capabilities and acquiring promising candidate drugs, has swept away concerns over a decline in Sumitomo Dainippon's earnings after its patent for the Latuda antipsychotic, whose sales account for 40 pct of its total, expires in the United States in February 2023, Hiroshi Nomura, president of the Osaka-based firm, said at a press conference at the firm's Tokyo head office.

Switch to Japanese